Jump Financial’s Redhill Biopharma RDHL Stock Holding History

Jump Financial’s Portfolio RDHL Stock Details RDHL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-32	Closed	-$82K	–	1848
2021 Q4	$82K	Buy	+32	New	+$128K	0.01%	1252
2021 Q3	–	Sell	-15	Closed	-$101K	–	1433
2021 Q2	$101K	Buy	+15	New	+$104K	0.01%	976
2021 Q1	–	Sell	-10	Closed	-$84K	–	1224
2020 Q4	$84K	Buy	+10	New	+$89.9K	0.01%	879

Other funds holding RDHL

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Claret Asset Management Montreal, Quebec, Canada $837M AUM 25.51% 1-Year Est. Return

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Jump Financial's RDHL Position: Q1 2022 in Review

Jump Financial sold out of Redhill Biopharma (RDHL) in Q1 2022, closing a stake of 32 shares — an estimated $82K sold.

Jump Financial first reported a position in RDHL in Q4 2020 and held it in 3 quarters. The position peaked at $101K in Q2 2021. 43 funds tracked by Wall St. Rank hold RDHL as of Q1 2022.

Jump Financial reported no remaining Redhill Biopharma position as of Q1 2022 after selling out during the quarter.
Jump Financial sold 32 Redhill Biopharma shares in Q1 2022, an estimated $82K.
Jump Financial first reported a position in Redhill Biopharma in Q4 2020 and held it in 3 quarters.
Jump Financial's Redhill Biopharma position peaked at $101K in Q2 2021.
43 funds tracked by Wall St. Rank held Redhill Biopharma as of Q1 2022.

Based on Jump Financial's 13F filing for Q1 2022, filed 12 May 2022.